The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
Open accessAbstract
Elevated levels of non‐esterified fatty acids (NEFA) play a role in insulin resistance, impaired beta‐cell function and they are a denominator of the abnormal atherogenic lipid profile that characterizes obese patients with type 2 diabetes (T2DM). We hypothesized that the GLP‐1 receptor agonist liraglutide, in combination with metformin, would reduce lipolysis. In a randomized, double‐blind, placebo‐controlled, cross‐over trial, 41 T2DM patients with coronary artery disease were randomized and treated with liraglutide‐metformin vs placebo‐metformin during 12‐ + 12‐week periods with a wash‐out period of at least 2 weeks before and between the intervention periods. NEFA kinetics were estimated using the Boston Minimal Model of NEFA metabolism, with plasma NEFA and glucose levels measured during a standard 180‐minute frequently sampled intravenous glucose tolerance test. Liraglutide‐metformin reduced estimates of lipolysis. Furthermore, placebo‐metformin increased estimates of lipid oxidation, while treatment with liraglutide eliminated this effect. We conclude that liraglutide exerts a clinically relevant reduction in estimates of lipolysis and lipid oxidation which is explained, in part, by improved insulin secretion, as revealed by an intravenous glucose tolerance test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recorded clinical data in 2019 demonstrated that liraglutide effectively diminishes adiposity and overall body fat by enhancing lipolysis among patients with T2DM who are obese.
“Recorded clinical data in 2019 demonstrated that liraglutide, a specific GLP-1RA, effectively diminishes adiposity and overall body fat by enhancing lipolysis among patients with T2DM who are obese. 76”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [76]
The Lipolysis results report that liraglutide reduced, rather than enhanced, estimated lipolysis compared with placebo. The paper reports weight loss, but does not establish a reduction in overall body fat or attribute weight loss to enhanced lipolysis. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Metabolic Flexibility in Health and Disease
Goodpaster, B. H., & Sparks, L. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.015 · Cited by 995
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 905
Fatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896
SERUM-FREE-FATTY-ACIDS AND THEIR RELATION TO COMPLICATIONS AFTER ACUTE MYOCARDIAL INFARCTION
Rutenberg, H., Pamintuan, J. C., & Soloff, L. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90261-x · Cited by 85
New and emerging regulators of intestinal lipoprotein secretion
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 58
Kang, Z., Deng, Y., Zhou, Y., Fan, R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2012) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 55
McLaughlin, T., Abbasi, F., Lamendola, C. A., et al. (2001) · Metabolism · doi:10.1053/meta.2001.24220 · Cited by 45
Kim, S. H., Liu, A., Ariel, D., Abbasi, F., Lamendola, C. A., Grove, K., Tomasso, V., & Reaven, G. M. (2013) · Diabetologia · doi:10.1007/s00125-013-3134-3 · Cited by 40
A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge
Boston, R., & Moate, P. J. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00749.2007 · Cited by 37
Self-citationLabbé, S. M., Noll, C., Grenier–Larouche, T., Kunach, M., Bouffard, L., Phoenix, S., Guérin, B., Baillargeon, J., Langlois, M., Turcotte, É. E., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00638.2013 · Cited by 28
Ohira, M., Miyashita, Y., Murano, T., Watanabe, F., & Shirai, K. (2009) · Metabolism · doi:10.1016/j.metabol.2009.04.024 · Cited by 28
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes
Basu, R., Basu, A., Chandramouli, V., Norby, B., Dicke, B. A., Shah, P. J., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetologia · doi:10.1007/s00125-008-1138-1 · Cited by 18
Anholm, C., Kumarathurai, P., Pedersen, L., Nielsen, O., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., & Haugaard, S. (2017) · Diabetes, obesity and metabolism · doi:10.1111/dom.12891 · Cited by 18
Self-citationAstiarraga, B., Chueire, V. B., de Souza, A. L., Moreira, R. P., Alegre, S. M., Natali, A., Tura, A., Mari, A., Ferrannini, E., & Muscelli, E. (2018) · Diabetologia · doi:10.1007/s00125-018-4633-z · Cited by 18
Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome
Arca, M. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)50004-4 · Cited by 17
Flagged first, then by citations
Cited by
Sorted by citations
Metabolism of vascular smooth muscle cells in vascular diseases
Shi, J., Yang, Y., Cheng, A., Xu, G., & He, F. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00220.2020 · Cited by 366
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Austregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Metadata
- Authors
- Anholm, C., Kumarathurai, P., Samkani, A., Pedersen, L. R., Boston, R. C., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., & Haugaard, S. B.
- Affiliations
- Amager Hospital (DK)
- Bispebjerg Hospital (DK)
- The University of Melbourne (AU)
- Hvidovre Hospital (DK)
- Corresponding author
- Anholm, Christian
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-05-29
- Volume
- 21
- Issue
- 8
- Pages
- 2012-2016
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2943611997
- Cited by
- 22
- References
- 16
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 2
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, GLP-1 receptor agonists, lipolysis, lipid oxidation, free fatty acids, type 2 diabetes, coronary artery disease, obesity, metformin, insulin secretion, insulin resistance, atherogenic lipid profile
- MeSH terms
- Liraglutide, Aged, Blood Glucose, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fatty Acids, Nonesterified, Female, Humans, Hypoglycemic Agents, Lipolysis, Male, Metformin, Middle Aged, Obesity, Oxidation-Reduction, Treatment Outcome, Cross-Over Studies, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
